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Objectives. The purpose of the present study was to compare the
radial approach with the femoral approach for coronary stenting
in patients with acute coronary syndromes.
Background. Aggressive anticoagulation in patients with acute
coronary syndromes increases the risk of femoral vascular com-
plications. The transradial approach has the potential to signifi-
cantly reduce the incidence of access site bleeding complications
in this group of patients.
Methods. One hundred forty-two patients with acute coronary
syndromes undergoing coronary stenting were prospectively ran-
domized to have their procedure performed from either the radial
or femoral access site and the results compared.
Results. Nine of 74 patients randomized to the radial group
crossed over to the femoral group (6 negative Allen tests, 3 access
failures). Patient demographics were the same in both groups.
Primary success was identical: 96% radial, 96% femoral, ns. There
were no procedural myocardial infarctions or deaths, and no
patient was referred for emergency bypass surgery. There were no
access site bleeding complications in the radial group as opposed
to 3 (4%) in the femoral group, p < 0.01. Postprocedure length of
stay, days (1.4 6 0.2 radial vs. 2.3 6 0.4 femoral, p < 0.01) as well
as total hospital length of stay (3.0 6 0.3 radial vs. 4.5 6 0.5
femoral, p < 0.01) were significantly reduced in the radial group.
Total hospital charge was also significantly lower in the radial
group ($20,476 6 811 radial versus $23,389 6 1,180 femoral, p <
0.01).
Conclusion. Coronary stenting from the radial approach is
efficacious in patients with acute coronary syndromes. Access site
bleeding complications are less, and early ambulation results in a
shorter hospital length of stay. There was a 15% reduction in total
hospital charge in the radial group.
(J Am Coll Cardiol 1998;32:572–6)
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The transradial approach for coronary intervention was first
introduced by Kiemeneij et al. and its benefits have subse-
quently been clearly demonstrated in several studies from
different centers (1). Access site bleeding complications are
virtually eliminated (2–4). Patients may ambulate immediately
after the procedure and hospital lengths of stay are signifi-
cantly reduced (2–4). There is a substantial economic benefit
with the transradial approach, and this can be demonstrated
with either evaluation of hospital costs or total hospital charge
(3–6). Procedural morbidity is less, and patients overwhelm-
ingly prefer the transradial over the femoral approach (2,7).
The contemporary management of acute coronary syn-
dromes involves intensive anticoagulation which may include
thrombolytic therapy or platelet glycoprotein IIb/IIIa receptor
inhibition in addition to heparin and aspirin. Coronary stenting
from the femoral approach in these patients is associated with
an increased incidence of access site complications (8–12).
These bleeding vascular complications are an important cause
of increased patient morbidity, longer hospital stays, and
higher hospital costs (12–14). Thus, the transradial approach
may be particularly beneficial in patients with acute coronary
syndromes.
The purpose of the present randomized prospective study
was to evaluate the transradial approach in these patients.
Methods
Patients. The study population was drawn from the 341
patients with acute coronary syndromes who were admitted to
our hospital between April and July 1997. All patients within
this group who underwent coronary stenting were included in
the study. There were 142 patients (42%) who met this criteria.
The remaining patients were managed with medications alone,
angioplasty alone, or coronary bypass surgery. The study was
performed in compliance with our Human Studies Committee
and written informed consent was obtained in every patient.
Acute coronary syndromes included unstable angina,
non-Q wave myocardial infarction, and transmural myocardial
infarction. Unstable angina was defined as new onset or rest
angina associated with ST and T wave changes and .75%
coronary stenosis by visual angiographic assessment corre-
sponding to the distribution of the EKG changes. Patients with
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the same findings and, in addition, a significant rise in their
serum CPK level, were considered to have a nontransmural
myocardial infarction. Transmural myocardial infarction was
defined by the presence of persistent ST segment elevation or
Q wave formation associated with their chest pain syndrome.
Most of these patients were managed with thrombolytic ther-
apy at an outside hospital and subsequently referred to our
institution for possible intervention.
Most patients underwent cardiac angiography and the
coronary intervention as part of the same procedure. Thus,
randomization to either radial or femoral group access oc-
curred prior to the catheterization procedure. Patients were
included in the study only if coronary stenting was planned. All
of the transradial procedures were performed by two of the
authors (TM, JS). Transfemoral procedures were performed
by five different interventionalists (TM, JS, WN, MZ, GR).
All patients randomized to the radial group underwent an
Allen test as well as Doppler analysis of the radial and ulnar
arteries prior to the procedure (15). Patients randomized to
the radial group whose evaluation suggested an incomplete
palmer arch had their procedures performed from the femoral
approach. Patients randomized to the radial group whose
radial artery could not be successfully catheterized were
counted as a radial failure and had their procedure performed
from the femoral approach.
Procedure. The technique of radial artery cannulation has
been previously described (16). This technique was slightly
altered during the latter stages of the study, in that verapamil
2 mg was injected directly into the radial artery prior to
insertion of the sheath and these patients were not premedi-
cated with Procardia sublingually. Catheterization was per-
formed with 6 French Cordis multipurpose diagnostic cathe-
ters. Subsequent angioplasty and stent implantation was
performed using 6 French SCIMED 0.064 Triguide guide
catheters. Alternatively, Schneider 0.061 Pink Power guide
catheters were commonly utilized when deep seating of the
guide catheter was required (16).
In the femoral group, catheterization was performed using
6 French diagnostic catheters, usually Judkins curves. All
patients in the femoral group underwent coronary stenting
using the same bare stent technique as in the radial group.
Twenty of these patients had their procedure performed using
6 French guide catheters, and 57 using 7 French guide cathe-
ters.
The bare stent technique used in all patients in the present
study has been previously described (16). Palmaz-Schatz stents
were removed from the manufacturer’s delivery system and
hand crimped on a noncompliant balloon. All stents were
delivered using 14–18 atmosphere balloon inflations. Subse-
quent postdelivery inflations were performed as dictated by the
angiographic appearance of the lesion. Intravascular ultra-
sound is not a part of our routine clinical practice and was not
performed in the present study.
Anticoagulation. All patients received 325 mg aspirin prior
to the procedure. Heparin 5,000 units was administered during
the catheterization procedure and additional heparin was
given on a weight-adjusted basis prior to the interventional
procedure. Activated clotting times were measured q 30 min-
utes during the procedure and were maintained greater than
300 s with additional heparin as necessary. Abciximab was
administered as clinically indicated during the procedure. A
weight-adjusted intracoronary or intravenous dose was admin-
istered and this was followed by a 12-h intravenous infusion
without additional heparin therapy. In those patients who did
not receive ReoPro, intravenous heparin was continued for
12–24 h at a dose sufficient to maintain the partial thrombo-
plastin time in the 50–100 s range. All patients received
ticlopidine 500 mg p.o. at the completion of the procedure
followed by 250 mg p.o. b.i.d. for 2–4 weeks. None of the
patients were pretreated with ticlopidine.
Sheath management. In the radial group, the radial artery
sheath was immediately removed at the completion of the
procedure and hemostasis was obtained using a selective radial
artery compression device (17). In these patients, anticoagula-
tion was continued without interruption. The compression
device was removed in 2–4 h and a nonocclusive pressure
bandage was subsequently placed over the operative site.
Patients were then allowed to ambulate immediately, unless
their clinical status dictated otherwise.
In the femoral group, patients were transferred to a holding
area where the sheath was removed when the activated clotting
time was less than 180 s. Hemostasis was obtained using
manual compression followed by a FemoStop which was left in
place for 4–6 h. These patients remained at bedrest overnight
and were allowed to ambulate the following morning as
clinically indicated.
Data management and procedural analysis. Procedural
success was defined as a reduction of the target lesion to less
than 25% luminal diameter by visual angiographic assessment
without complication. Data were collected from analysis of the
patient’s hospital charts, angioplasty event reports, cine-
angiograms, and UB-92 Discharge Forms. Lesions were clas-
sified according to the NHLBI Task Force on PTCA (18).
Access site complications were defined as a bleeding vascular
complication that prolonged hospitalization. Procedural myo-
cardial infarction was defined as an abnormal CPK elevation
following the procedure.
Statistical analysis was performed using an unpaired t test.
The differences between groups were statistically significant
with a p value of ,0.01. Means were calculated and expressed
as standard error of the mean.
Abbreviations and Acronyms
EKG 5 electrocardiogram
CPK 5 creatinine phosphokinase
NHLBI 5 National Heart Lung and Blood Institute
PTCA 5 Percutaneous transluminal coronary angioplasty
573JACC Vol. 32, No. 3 MANN ET AL.
September 1998;572–6 TRANSRADIAL STENTING IN ACUTE CORONARY SYNDROMES
Results
Study population. The outcome of patients randomized to
radial access is shown in Figure 1. During the course of the
study, six of the 74 (8%) patients randomized to the radial
group had a negative Allen test and/or Doppler examination
suggesting an incomplete palmer arch; these were included in
the femoral group. Of the remaining 68 patients in the radial
group, 65 patients had their procedures performed transradi-
ally. In three patients, the radial artery was not successfully
cannulated, and these were also included in the femoral group.
Thus, 77 patients who had their procedures performed from
the femoral approach included 9 radial crossovers.
Baseline demographic and clinical characteristics are shown
in Table 1. The mean age was the same in both groups. The
majority of patients were males, although 23 (35%) of patients
in the radial group as opposed to 25 (32%) in the femoral
group, ns, were female.
There was no significant difference in the incidence of the
various acute coronary syndromes between the two study
groups. The majority of patients in both groups had unstable
angina. Twenty-eight (43%) in the radial group versus 34
(44%) in the femoral group (p 5 ns) had evidence of myocar-
dial infarction. A minority of patients presented with acute
transmural myocardial infarction, and this reflects the referral
patterns of our practice. No patient underwent direct angio-
plasty for his myocardial infarction. No patients presented with
cardiogenic shock, and none required intra-aortic balloon
counterpulsation.
There was no significant difference in the two groups in the
incidence of patients receiving tPA. A slightly higher percent-
age of patients in the radial group received ReoPro although
this difference was not significant. A minority of patients
received multiple stents, and the number of stents delivered
was the same in both groups (average 1.3 stents per patient).
Angiographic data are shown in Table 2. The vessel distri-
bution between the two groups was the same. Lesion morphol-
ogy was also the same in both groups. Note the majority of
patients did have complex lesion morphology although all had
TIMI grade III coronary flow at the time of the procedure.
Procedural outcome. The procedural outcomes in both
groups are shown in Table 3. Primary success was high in both
groups and not statistically different. Sixty-five of the 68
patients randomized to the radial approach had a successful
procedure (96%). The three primary failures were due to
inability to access the radial artery. All 65 patients whose radial
artery was cannulated had successful procedures (see Fig. 1).
Seventy-four of the 77 femoral patients had successful
procedures (96%). The three femoral failures were due to
inability to successfully stent the target lesion, and these
patients were managed with angioplasty alone. One of these
patients had stent embolization without clinical sequelae; the
stent was not retrieved and final location was uncertain.
There were no deaths in the present study and no patients
were referred for emergency bypass surgery. No patient had a
myocardial infarction as a result of their procedure.
Access site bleeding complications occurred only in the
femoral group. There were three (4%) large hematomas which
prolonged hospitalization. None of these required surgical
correction, although two required transfusion. No patients in
the radial group developed an access site bleeding complica-
Figure 1. Outcome of patients randomized to radial access.
Table 1. Baseline Clinical Characteristics of the Study Patients
Radial Femoral p Value
Patients 65 77 NS
Age, mean 63 62 NS
Female sex 23 (35%) 25 (32%) NS
Clinic presentation
Unstable angina 37 (57%) 42 (56%) NS
Non-Q myocardial infarction 19 (29%) 24 (30%) NS
Q myocardial infarction 9 (14%) 11 (14%) NS
Adjunctive therapy
tPA 13 (20%) 16 (21%) NS
Abciximab 10 (15%) 8 (10%) NS
Number of stents/patient 1.3 1.3 NS
Table 2. Baseline Angiographic Findings of the Study Patients
Radial Femoral p Value
Number of lesions treated 86 88 NS
Lesion location
LAD 32 35 NS
LCX 16 13 NS
RCA 24 26 NS
SVBG 11 9 NS
Other 3 5 NS
Lesion type
A 30 35 NS
B1 36 37 NS
B2 16 15 NS
C 4 1 NS
Table 3. Comparison of Procedural Results
Radial Femoral p Value
n 5 68 n 5 77
Primary success 65 (96%) 74 (96%) NS
Death/CABG/MI 0 0 NS
Access site complications 0 3 (4%) p , 0.01
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tion. This difference was statistically significant (p , 0.01). All
patients had a palpable radial artery postprocedure and no
patient had symptoms or physical signs of hand ischemia.
However, Doppler examination was not routinely performed
and the incidence of asymptomatic radial artery occlusion was
thus not determined.
Economic variables are shown in Table 4 and illustrated in
Figure 2. Preprocedure length of stay was slightly longer in the
femoral group although this difference was not statistically
significant (1.6 6 0.5, radial versus 2.1 6 0.4 femoral, ns).
Postprocedure length of stay was 1.4 6 0.2 days in the radial
group as compared to 2.3 6 0.4 days in the femoral group (p ,
0.01). Total hospital length of stay was 3.0 6 0.3 days in the
radial group as compared to 4.5 6 0.5 days in the femoral
group (p , 0.01). Total hospital charge was $20,476 6 811 in
the radial group as compared to $23,389 6 1,180 in the femoral
group (p , 0.01).
Discussion
The present study suggests that the transradial approach has
important advantages for coronary stenting in patients with
acute coronary syndromes. In this randomized, prospective
trial, the primary success rate was the same (96%), regardless
of whether the procedure was performed from the radial or
femoral approach. However, access site bleeding complications
were significantly less in the transradial group. In addition,
more rapid ambulation in this group resulted in a shorter
hospital length of stay and a 15% reduction in total hospital
charge.
The pathogenesis of acute coronary syndromes involves the
disruption of atherosclerotic plaque with subsequent superim-
posed thrombus formation (19). Thus, aggressive antithrom-
botic therapy is a cornerstone of contemporary management of
these syndromes. All patients receive aspirin and intravenous
heparin; in addition, selected patients receive thrombolytic
therapy and/or platelet glycoprotein IIb/IIIa receptor inhibi-
tors. Transfemoral coronary intervention in the presence of
this intensive antithrombotic therapy is associated with a
significantly increased risk of access site complications (8–12).
The incidence of these groin complications has been re-
duced by several strategies. These include the use of ticlopi-
dine and aspirin alone following coronary stenting, weight-
adjusting the dose of both heparin and platelet glycoprotein
IIb/IIIa inhibitors, and the use of smaller guide catheters.
Postprocedure mechanical devices, sutures, and vascular seal-
ants are being increasingly used for local hemostasis. In the
present study, the incidence of bleeding vascular complications
in the femoral group was 4%, which is as low as has been
reported in the literature in a controlled study of these
unstable patients.
Benefits of the transradial approach. In spite of this low
incidence of bleeding vascular complications in the femoral
group, access site complications were still reduced in the
present study by using the transradial approach. Indeed, no
bleeding complications were encountered in the radial group.
The superficial location of the radial artery allows easy hemo-
stasis, and the use of a mechanical compression device mini-
mizes utilization of personnel (17,20).
The ability to rapidly ambulate patients is a significant
benefit of the transradial approach. In the present study, both
postprocedure and total hospital lengths of stay were signifi-
cantly shortened. It has previously been demonstrated that this
rapid ambulation results in less immediate and overall discom-
fort with the catheterization procedure (7). As a result, pa-
tients overwhelmingly prefer having these procedures per-
formed from the radial approach (2,7).
Total hospital charge was reduced 15% in the radial group
as compared to the femoral group. While a detailed cost
analysis was not made, this basic figure is important as it
represents a bottom line charge presented to the patient and
his insurance carriers. This cost savings with the radial ap-
proach has now been repeatedly demonstrated (2,3,5,6). While
not specifically evaluated in the present study, previous reports
have demonstrated this economic benefit is the result of a
shorter hospital stay as well as fewer diagnostic and therapeu-
tic procedures for stent related bleeding vascular complica-
tions (5,6,13).
Limitations of the transradial approach. An important
criticism of the radial approach is that it is not suitable for
every patient. In the present study, 12% of the patients
randomized to the radial group subsequently had the proce-
dure performed via the transfemoral approach. This was a
result of either a negative Allen test or failure to obtain
vascular access. The need for the use of small guide catheters
has been felt to be a significant limitation of the transradial
approach because of poor visualization and inadequate backup
support (21). However, with experience and the recent contin-
ued miniaturization of interventional devices, this no longer is
a serious drawback. Indeed, in the present study, no patient
Figure 2. Comparison of economic variables between femoral and
radial groups. PPLOS 5 postprocedure length of stay. THLOS 5 total
hospital length of stay. TC 5 total hospital charge.
Table 4. Comparison of Economic Variables
Radial Femoral p Value
Postprocedure length of stay, days 1.4 2.3 p , 0.01
Total hospital length of stay, days 3.0 4.5 p , 0.01
Total hospital charge, $ 20,476 23,389 p , 0.01
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crossed over to the femoral approach for technical reasons and
the primary success rate was equivalent in both groups. Several
reports attest to the use of the transradial approach in virtually
all clinical situations (22–31).
Coronary stenting from the radial approach involves a
significant learning curve, particularly when the bare stent
technique is utilized (16). Alternative 6 French stent delivery
systems are now available, and this should significantly shorten
the learning curve. It should be emphasized that the present
study was performed by operators with substantial transradial
experience, as the benefits of the technique are less apparent
with inexperienced operators (32,33).
An important limitation of the present study is the lack of
follow-up Doppler information regarding the patency of the
radial artery from which the procedure was performed. Al-
though no patient in the present study had an absent pulse or
symptoms suggesting vascular ischemia of the hand, it is likely
that asymptomatic radial artery occlusion occurred in a small
percentage of patients. Previous studies have demonstrated the
incidence of asymptomatic radial occlusion in the 3–5% range,
but the benign nature of this problem has been emphasized
(3,15,32).
Conclusion. The present study demonstrates that transra-
dial coronary stenting is a useful procedure in managing high
risk coronary patients. In patients with unstable coronary
syndromes, procedural success rates are similar to the femoral
approach and there is a significant reduction in access site
complications. Early ambulation leads to a reduction in total
hospital stay and a significant reduction in total hospital
charge.
The editorial assistance of Ms. Ann Rouse is gratefully acknowledged.
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